Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer.
1. What is the rationale for the combined use of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer? (00:18-01:18)
2. Could you give us an overview of the COSMIC-021 study and the initial efficacy and safety findings for cohort 6? (01:18-03:15)
3. What are the findings for the expanded cohort, and what is their clinical significance? (03:15-09:35)
Disclosures: Neeraj Agarwall discloses lifetime COI Consultancy to Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics and Seattle Genetics. Research funding to his institution: Astra Zeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda and Tracon.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO 2021 Annual Meeting.
Share this Video
Related Videos In Prostate Cancer
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]
Axel Merseburger: Highlights of EAU23
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!